API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/29/2871068/0/en/Atea-Announces-Presentation-of-Data-Highlighting-Favorable-Safety-Profile-of-Bemnifosbuvir-at-ESCMID-Global-2024.html
https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html
https://www.globenewswire.com//news-release/2023/11/13/2778876/0/en/Atea-Pharmaceuticals-Presents-Promising-Bemnifosbuvir-and-Ruzasvir-Combination-Data-for-the-Treatment-of-Hepatitis-C-Virus-at-AASLD-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/11/02/2772115/0/en/Atea-Pharmaceuticals-to-Present-Bemnifosbuvir-and-Ruzasvir-Data-for-the-Treatment-of-Hepatitis-C-Virus-at-AASLD-The-Liver-Meeting-2023.html
https://www.globenewswire.com/news-release/2023/04/25/2653701/0/en/Atea-Pharmaceuticals-Announces-U-S-FDA-Fast-Track-Designation-Granted-to-Bemnifosbuvir-an-Investigational-Oral-Antiviral-for-the-Treatment-of-COVID-19.html
https://www.clinicaltrialsarena.com/news/atea-results-bemnifosbuvir-covid-19/
https://www.globenewswire.com/news-release/2023/03/08/2622862/0/en/New-Data-Showcasing-Favorable-Profile-of-Bemnifosbuvir-for-Treatment-of-COVID-19-and-Hepatitis-C-to-be-Presented-at-2023-International-Conference-on-Antiviral-Research.html
https://www.globenewswire.com/news-release/2022/03/28/2410826/0/en/Atea-Pharmaceuticals-Reports-Nonclinical-Bemnifosbuvir-AT-527-Toxicology-Data-at-Society-of-Toxicology-61st-Annual-Meeting.html
https://www.globenewswire.com/news-release/2021/06/30/2255518/0/en/Atea-s-AT-527-an-Oral-Antiviral-Drug-Candidate-Reduces-Viral-Replication-in-Hospitalized-Patients-with-COVID-19-in-Phase-2-Interim-Analysis.html